The effect of drugs commonly used in the treatment of equine articular disorders on the activity of equine matrix metalloproteinase-2 and 9.

This research explores the impact of various drugs typically used in treating horse joint diseases on the activity of certain enzymes called Matrix Metalloproteinase-2 and 9. The study concludes that while some drugs may affect these enzymes, the concentration required for this effect is unlikely to be sustained in real-life circumstances.

Objective of the Research

• The focus of the study lies in understanding if common pharmacological agents used in the treatment of equine articular disorders have any direct effect on the activity of two specific enzymes – matrix metalloproteinase-2 and 9 (MMPs-2 and 9).

Background

• The deterioration of articular cartilage – a key pathological symptom in osteoarthritis – is believed to be facilitated by certain enzymes. One group of these enzymes, known as the matrix metalloproteinases (MMPs), are thought to be responsible for the degradation of articular cartilage matrix.
• MMP-2 and MMP-9, in particular, are connected to the degradation process. Using drugs to inhibit the activity of these enzymes might potentially offer a therapeutic solution for dealing with articular disorders.

Methodology

• The researchers used affinity chromatography to purify the specific MMPs from equine cell cultures.
• They then tested the ability of various drugs – including phenylbutazone, flunixin, betamethasone, dexamethasone, and others – to inhibit the activity of the purified equine MMPs-2 and 9. This was done through two degradation assays.

Findings

• The results indicated that while some drugs do have a direct effect on the activity of MMP-2 and MMP-9, the effect could only be obtained at concentrations unlikely to be sustainable in vivo – that is, in a living organism.

Conclusion

• The study concludes that it’s unlikely for a pharmacological agent, currently used for treatment in horses, to have a significant impact on the activity of MMP-2 and MMP-9 enzymes. This suggests that new approaches may be needed to combat enzymatically mediated degradation of articular cartilage in horses.